Study #2024-0298
A multicenter, randomized, double-blind, vehicle-controlled, phase 3 efficacy and safety study of Patidegib Gel 2% for the reduction of disease burden of persistently developing basal cell carcinomas (BCCs) in subjects with Gorlin syndrome
MD Anderson Study Status
Enrolling
Treatment Agent
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Description
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Gorlin Syndrome
Study phase:
Phase III
Physician name:
Michael Migden
Department:
Dermatology
For general questions about clinical trials:
1-888-704-1252
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.